Table 1 Summary of subject information for the four cohorts
Cohort 1 | CDR 0 | CDR 0.5 | CDR 1 | CDR 2 | |
|---|---|---|---|---|---|
N | 18 | 20 | 13 | 13 | |
Age | 78.8 ± 5.83 | 71.9 ± 7.929 | 81.1 ± 5.27 | 83.8 ± 7.01 | |
Gender (F %) | 72.2 | 55.0 | 100 | 84.6 | |
MMSE (score) | - | 25.5 ± 2.86 | 19.1 ± 3.28 | 16.2 ± 2.68 | |
HDS-R (score) | - | 25.3 ± 3.42 | 18.3 ± 4.40 | 14.5 ± 3.78 | |
Aβ 40 (pg/mL) | 9288 ± 3663 | 13070 ± 4798 | 14450 ± 3846 | 11460 ± 4768 | |
Aβ 42 (pg/mL) | 633.8 ± 292.8 | 506.6 ± 194.7 | 656.7± 380.3 | 415.6 ± 228.2 | |
p3-Alcα (pg/mL) | 7086 ±1971 | 8548 ± 2373 | 9238 ± 2243 | 6902 ± 2345 | |
Cohort 2 | CDR 0 | CDR 0.5 | CDR 1 | ||
N | 20 | 20 | 13 | ||
Age | 74.1 ± 6.61 | 75.5 ± 5.61 | 76.2 ± 6.22 | ||
Gender | 50.0 | 55.0 | 53.8 | ||
MMSE (score) | 28.7 ± 1.27 | 26.3 ± 2.33 | 23.1 ± 3.71 | ||
Aβ 40 (pg/mL) | 10450 ± 3872 | 9758 ± 4527 | 9080 ± 3953 | ||
Aβ 42 (pg/mL) | 802.6 ± 185.2 | 322.0 ± 73.05 | 292.7 ± 64.62 | ||
p3-Alcα (pg/mL) | 9569 ± 3604 | 9538 ± 3225 | 8111 ± 2666 | ||
Cohort 3 | CDR 0 | CDR 0.5 | CDR 1 | CDR 2-3 | FTLD |
N | 23 | 9 | 13 | 12 | 37 |
Age | 66.3 ± 9.26 | 68.0 ± 8.51 | 69.7 ± 10.1 | 69.2 ± 9.73 | 69.6 ± 11.6 |
Gender (F%) | 47.8 | 55.6 | 61.5 | 50.0 | 45.9 |
MMSE (score) | - | 26.9 ± 1.27 | 21.4 ± 2.10 | 11.7 ± 5.85 | 16.3 ± 8.62 |
Aβ 40 (pg/mL) | 6392 ± 1876 | 7066 ± 4707 | 6930 ± 4256 | 6316 ± 4006 | 4487 ± 2824 |
Aβ 42 (pg/mL) | 795.7 ± 280.1 | 383.6 ± 317.6 | 401.0 ± 333.6 | 335.2 ± 218.1 | 387.8 ± 307.5 |
p3-Alcα (pg/mL) | 5254 ± 1365 | 6047 ± 3336 | 5918 ± 3404 | 5441 ± 2323 | 3557 ± 1816 |
Cohort 4 | |||||
N | 57 | ||||
Age | 68.2 ± 7.82 | ||||
Gender (F%) | 64.9 | ||||
MMSE (score) | 28.5 ± 2.18 | ||||
CSF Aβ 40 (pg/mL) | 7800 ± 3716 | ||||
CSF Aβ 42 (pg/mL) | 417.1 ± 216.6 | ||||